MedTrace Logo

The clonoSEQ® Watch Registry

NCT04545333 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 465

Last updated 2024-08-01

No results posted yet for this study

Summary

This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.

Conditions

Interventions

DIAGNOSTIC_TEST

clonoSEQ Assay

minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells

Sponsors & Collaborators

  • Adaptive Biotechnologies

    lead INDUSTRY

Principal Investigators

  • Heidi Simmons, PhD · Adaptive Biotechnologies

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-13
Primary Completion
2023-10-01
Completion
2023-10-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04545333 on ClinicalTrials.gov